Dr. Paul Offit Receives 2018 Albert B. Sabin Gold Medal

WASHINGTON, D.C. – April 24, 2018 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Paul Offit with the 2018 Albert B. Sabin Gold Medal. Sabin will recognize Dr. Offit for his contributions as co-inventor of an oral rotavirus vaccine and his leadership as one of the United States’ most vocal and dedicated advocates for immunization.

WHO recommends use of first typhoid conjugate vaccine

Geneva, Switzerland – April 3, 2018 – The World Health Organization (WHO) recommends the introduction of typhoid conjugate vaccine (TCV) for infants and children over six months of age in typhoid-endemic countries. This new policy will help ensure access to typhoid vaccination in communities most impacted by the disease, which is responsible for nearly 12 million infections and between 128,000 and 161,000 deaths a year.

Sabin to tackle pandemic flu

WASHINGTON, D.C. – January 8, 2018 – The Sabin Vaccine Institute, a non-profit global health organization dedicated to enabling vaccine innovation, making vaccines more accessible and expanding immunization across the globe, is pleased to announce a new three-year $6.6 million grant to help speed the development of next generation influenza vaccines and support related immunization issues. This work is generously supported by the Page Family Donor Advised Fund.

First typhoid conjugate vaccine achieves WHO prequalification, a key step in protecting children and reducing the burden of typhoid

Geneva, Switzerland – January 3, 2018 – A typhoid conjugate vaccine has been prequalified by the World Health Organization (WHO), bringing the vaccine one step closer to reaching millions more people at risk of typhoid.